About Rezolute Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.rezolutebio.com/
Frequently Asked Questions
What is the 52-week range for RZLT?
The 52-week high is $11.457 and the 52-week low is $1.07.
What is the P/E ratio for RZLT?
The P/E ratio data is currently unavailable.
What is the dividend yield for RZLT?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -62.99%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 4.97.
Analyst Recommendation Trends
Wall Street analyst consensus for RZLT over the last few months:
Latest RZLT News
Why Vicor Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Vicor shares surged 12% after raising Q3 growth guidance above 30%; Roze AI led gainers, while Corteva plunged 57% premarket.
Lake Street Initiates Coverage On Rezolute with Buy Rating, Announces Price Target of $9
Lake Street analyst Daniel Brims initiates coverage on Rezolute (NASDAQ:RZLT) with a Buy rating and announces Price Target of $9.
This Staar Surgical Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Analysts upgraded STAA, NFLX, SFIX, with ratings moving toward Buy or Neutral and mixed price-target changes.
Craig-Hallum Upgrades Rezolute to Buy, Raises Price Target to $7
Craig-Hallum analyst Albert Lowe upgrades Rezolute (NASDAQ:RZLT) from Hold to Buy and raises the price target from $4 to $7.
5 Stock Picks Last Week From Wall Street's Most Accurate Analysts
U.S. stocks rose as oil fell on Strait of Hormuz hopes; Benzinga highlights top analysts’ picks: OKTA, AKAM and TELA.
HC Wainwright & Co. Maintains Buy on Rezolute, Raises Price Target to $10
HC Wainwright & Co. analyst Douglas Tsao maintains Rezolute (NASDAQ:RZLT) with a Buy and raises the price target from $5 to $10.
Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today reported financial results and provided a business update for the fourth quarter and full fiscal year ended June 30, 2026. Tumor HI upLIFT, a Phase 3, single-arm, open label study in up to 16 hospitalized participants for the treatment of tumo
Rezolute Q4 EPS $(0.20) Misses $(0.15) Estimate
Rezolute (NASDAQ:RZLT) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.15) by 33.33 percent. This is a 23.08 percent increase over losses of $(0.26) per share from the
Rezolute: Initiating At Sell Despite Attempts To Rescue Ersodetug Following sunRIZE Upset
Phase 3 sunRIZE miss in congenital hyperinsulinism hurts FDA odds; limited upside and high cash burn signal dilution risk. Click for more on RZLT stock.
Sector Update: Healthcare Stocks Softer Late Afternoon
Healthcare stocks were lower late Wednesday afternoon with the NYSE Healthcare Index and the State S
Sector Update: Healthcare Stocks Decline in Afternoon Trading
Healthcare stocks were lower Wednesday afternoon, with the NYSE Healthcare Index down 0.3% and the S
Rezolute FDA Review Continues After Phase 3 sunRIZE Study Missed Primary Endpoint
Rezolute (NASDAQ:RZLT) said the FDA is continuing its review of additional Phase 3 sunRIZE data for ersodetug in congenital hyperinsulinism after the study failed to meet its primary endpoint, leaving the potential regulatory path unresolved and without a specific timeline for agency feedback. Key Investor TakeawaysThe FDA review remains ongoing as the agency evaluates whether there is a potential regulatory path forward for ersodetug in congenital hyperinsulinism.
Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
Data from the Phase 3 sunRIZE study remains under review by FDA The OLE Phase of the study is ongoing, with a high participation rate and several indicators of improved glycemic control, including a notable reduction in the use of background standard of care therapies Enrollment continues in the Phase 3 upLIFT study in tumor HI and the Company remains on track to report topline results before the end of 2026 REDWOOD CITY, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (
Rezolute Said FDA Is Still Reviewing Ersodetug Submission In Congenital Hyperinsulinism; The Company Continues To Await Feedback And Reserves The Ability To Request Formal Meeting Under Regulatory Timeline
Data from the Phase 3 sunRIZE study remains under review by FDA The OLE Phase of the study is ongoing, with a high participation rate and several indicators of improved glycemic control, including a notable reduction in
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-02 | Karnawat Sunil Ratilal | -2,267 | $4.5 | $10,202 |
| 2026-07-02 | ROBERTS BRIAN KENNETH | -3,062 | $4.99 | $15,279 |
| 2026-07-02 | Evans Daron | -3,062 | $4.99 | $15,279 |
| 2026-07-02 | Elam Nevan C | -8,004 | $4.99 | $39,940 |
| 2026-03-30 | Evans Daron | +10,000 | $2.85 | $28,500 |
| 2026-03-02 | ROBERTS BRIAN KENNETH | -11,439 | $2.99 | $34,203 |
| 2026-03-02 | Evans Daron | -11,438 | $2.99 | $34,200 |
| 2026-03-02 | Elam Nevan C | -27,618 | $2.99 | $82,578 |
| 2025-12-16 | Hogenhuis Wladimir | +5,650 | $1.69 | $9,549 |
| 2025-12-16 | ROBERTS BRIAN KENNETH | +28,000 | $1.7 | $47,600 |
| 2025-12-15 | Karnawat Sunil Ratilal | +100 | $1.6 | $160 |
| 2025-12-15 | Karnawat Sunil Ratilal | +12,000 | $1.6199 | $19,439 |
| 2025-12-15 | Evans Daron | +2,500 | $1.79 | $4,475 |
| 2025-12-15 | Evans Daron | +2,500 | $1.785 | $4,463 |
| 2025-12-15 | Evans Daron | +40,000 | $1.766 | $70,640 |
| 2025-12-15 | Elam Nevan C | +32,000 | $1.59 | $50,880 |
| 2025-12-09 | Evans Daron | +10,549 | $5.04 | $53,167 |
| 2025-11-19 | ROBERTS BRIAN KENNETH | +72,000 | - | - |
| 2025-11-19 | ROBERTS BRIAN KENNETH | +123,000 | - | - |
| 2025-11-19 | Karnawat Sunil Ratilal | +19,000 | - | - |
| 2025-11-19 | Karnawat Sunil Ratilal | +32,000 | - | - |
| 2025-11-19 | KREHER NERISSA | +12,000 | - | - |
| 2025-11-19 | KREHER NERISSA | +21,000 | - | - |
| 2025-11-19 | Hogenhuis Wladimir | +12,000 | - | - |
| 2025-11-19 | Hogenhuis Wladimir | +21,000 | - | - |
| 2025-11-19 | Harris Erik | +12,000 | - | - |
| 2025-11-19 | Harris Erik | +21,000 | - | - |
| 2025-11-19 | Kim Young-Jin | +12,000 | - | - |
| 2025-11-19 | Kim Young-Jin | +21,000 | - | - |
| 2025-11-19 | FAUCHET PHILIPPE | +12,000 | - | - |
| 2025-11-19 | FAUCHET PHILIPPE | +21,000 | - | - |
| 2025-11-19 | Evans Daron | +63,000 | - | - |
| 2025-11-19 | Evans Daron | +107,000 | - | - |
| 2025-11-19 | Labrucherie Gil M | +12,000 | - | - |
| 2025-11-19 | Labrucherie Gil M | +21,000 | - | - |
| 2025-11-19 | Elam Nevan C | +186,000 | - | - |
| 2025-11-19 | Elam Nevan C | +317,000 | - | - |